Daiichi Sankyo has submitted an sNDA to Japan’s Ministry of Health, Labour and Welfare for its oral, once-daily direct factor Xa-inhibitor, Lixiana (edoxaban tosilate hydrate). The company is seeking approval in new indications for non-valvular atrial fibrillation (AF) and symptomatic venous thromboembolism (VTE). The sNDA submission is based on data from an extensive global clinical trial program that compared treatment with once-daily edoxaban to warfarin, a current standard of care for...